190 related articles for article (PubMed ID: 22515110)
1. Determination of ferritin and hemosiderin iron in patients with normal iron stores and iron overload by serum ferritin kinetics.
Saito H; Tomita A; Ohashi H; Maeda H; Hayashi H; Naoe T
Nagoya J Med Sci; 2012 Feb; 74(1-2):39-49. PubMed ID: 22515110
[TBL] [Abstract][Full Text] [Related]
2. Increasing and decreasing phases of ferritin and hemosiderin iron determined by serum ferritin kinetics.
Saito H; Hayashi H; Tomita A; Ohashi H; Maeda H; Naoe T
Nagoya J Med Sci; 2013 Aug; 75(3-4):213-23. PubMed ID: 24640177
[TBL] [Abstract][Full Text] [Related]
3. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.
Phatak P; Brissot P; Wurster M; Adams PC; Bonkovsky HL; Gross J; Malfertheiner P; McLaren GD; Niederau C; Piperno A; Powell LW; Russo MW; Stoelzel U; Stremmel W; Griffel L; Lynch N; Zhang Y; Pietrangelo A
Hepatology; 2010 Nov; 52(5):1671-779. PubMed ID: 20814896
[TBL] [Abstract][Full Text] [Related]
4. Transformation rate between ferritin and hemosiderin assayed by serum ferritin kinetics in patients with normal iron stores and iron overload.
Saito H; Hayashi H
Nagoya J Med Sci; 2015 Nov; 77(4):571-83. PubMed ID: 26663936
[TBL] [Abstract][Full Text] [Related]
5. Storage Iron Turnover from a New Perspective.
Saito H
Acta Haematol; 2019; 141(4):201-208. PubMed ID: 30943466
[TBL] [Abstract][Full Text] [Related]
6. Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.
Porter JB; Lin KH; Beris P; Forni GL; Taher A; Habr D; Domokos G; Roubert B; Thein SL;
Eur J Haematol; 2011 Oct; 87(4):338-48. PubMed ID: 21649735
[TBL] [Abstract][Full Text] [Related]
7. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
Porter JB; Elalfy M; Taher A; Aydinok Y; Lee SH; Sutcharitchan P; El-Ali A; Han J; El-Beshlawy A
Eur J Haematol; 2017 Mar; 98(3):280-288. PubMed ID: 27859648
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of deferasirox in aplastic anemia patients with iron overload: a single arm, multi-center,prospective study in China].
Shi J; Chang H; Zhang L; Shao Y; Nie N; Zhang J; Huang J; Zhang L; Tang X; Quan R; Zheng C; Xiao H; Hu D; Hu L; Liu F; Zhou Y; Zheng Y; Zhang F
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):1-6. PubMed ID: 26876245
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.
Taher A; Cappellini MD; Vichinsky E; Galanello R; Piga A; Lawniczek T; Clark J; Habr D; Porter JB
Br J Haematol; 2009 Dec; 147(5):752-9. PubMed ID: 19764988
[TBL] [Abstract][Full Text] [Related]
11. METABOLISM OF IRON STORES.
Saito H
Nagoya J Med Sci; 2014 Aug; 76(3-4):235-254. PubMed ID: 25741033
[TBL] [Abstract][Full Text] [Related]
12. Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?
Karimi M; Azarkeivan A; Zareifar S; Cohan N; Bordbar MR; Haghpanah S
Hematology; 2012 Nov; 17(6):367-71. PubMed ID: 23168076
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study.
Cançado R; Melo MR; de Moraes Bastos R; Santos PC; Guerra-Shinohara EM; Chiattone C; Ballas SK
Eur J Haematol; 2015 Dec; 95(6):545-50. PubMed ID: 25684349
[TBL] [Abstract][Full Text] [Related]
14. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.
Cappellini MD; Porter J; El-Beshlawy A; Li CK; Seymour JF; Elalfy M; Gattermann N; Giraudier S; Lee JW; Chan LL; Lin KH; Rose C; Taher A; Thein SL; Viprakasit V; Habr D; Domokos G; Roubert B; Kattamis A;
Haematologica; 2010 Apr; 95(4):557-66. PubMed ID: 19951979
[TBL] [Abstract][Full Text] [Related]
15. Deferasirox (Exjade) for the treatment of iron overload.
Cappellini MD; Taher A
Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
[TBL] [Abstract][Full Text] [Related]
16. Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload.
Watanabe J; Sato K; Horiuchi T; Kato S; Hikota R; Maekawa T; Yamamura T; Kobayashi A; Osawa Y; Kobayashi S; Kimura F
Int J Hematol; 2014 Sep; 100(3):254-9. PubMed ID: 24986748
[TBL] [Abstract][Full Text] [Related]
17. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.
Ghoti H; Fibach E; Merkel D; Perez-Avraham G; Grisariu S; Rachmilewitz EA
Haematologica; 2010 Aug; 95(8):1433-4. PubMed ID: 20421274
[No Abstract] [Full Text] [Related]
18. Oral iron chelator deferasirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia.
Quarta A; Melpignano A; Quarta G
Acta Haematol; 2011; 125(4):219-21. PubMed ID: 21266801
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
Cheong JW; Kim HJ; Lee KH; Yoon SS; Lee JH; Park HS; Kim HY; Shim H; Seong CM; Kim CS; Chung J; Hyun MS; Jo DY; Jung CW; Sohn SK; Yoon HJ; Kim BS; Joo YD; Park CY; Min YH;
Transfusion; 2014 Jun; 54(6):1542-51. PubMed ID: 24313463
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
